Kazumasa Oya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazumasa Oya has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Yasuhiro Fujisawa
Department of Dermatology Ehime University Graduate School of Medicine Ehime Japan
10 shared publications - Yoshiyuki Nakamura
Department of Dermatology Institute of Medicine, University of Tsukuba Tsukuba Japan
9 shared publications Toshifumi Nomura
Department of Dermatology, Institute of Medicine University of Tsukuba Tsukuba Ibaraki Japan
7 shared publicationsYoshiyuki Ishii
Department of Dermatology, Institute of Medicine University of Tsukuba Tsukuba Ibaraki Japan
7 shared publications- Naoko Okiyama
Department of Dermatology Graduate School of Medical and Dental Sciences, Institute of Science Tokyo Tokyo Japan
6 shared publications - Toshifumi Nomura
Department of Dermatology, Institute of Medicine University of Tsukuba Tsukuba Ibaraki Japan
6 shared publications
Latest Publications
- 2 December 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6)
Clinical and histopathological features of alopecia associated with enfortumab vedotin treatment
- 2 December 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6)
Clinical and histopathological features of alopecia associated with enfortumab vedotin treatment
- 20 April 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (9) , e308-e309
Milia‐like appearance of vulvar syringoma
- 20 April 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (9) , e308-e309
Milia‐like appearance of vulvar syringoma
- 17 April 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (9) , e304-e305
COVID‐19‐associated pemphigus foliaceus exacerbated by toll‐like receptor 7 agonist
- 17 April 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (9) , e304-e305
COVID‐19‐associated pemphigus foliaceus exacerbated by toll‐like receptor 7 agonist
- 4 April 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (4) , 570-573
Pemphigoid ohne Schleimhautbeteiligung, mit IgG‐Antikörpern gegen die β3‐Untereinheit von Laminin‐332
- 4 April 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (4) , 570-573
Pemphigoid ohne Schleimhautbeteiligung, mit IgG‐Antikörpern gegen die β3‐Untereinheit von Laminin‐332
- 3 March 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (6) , 807-815
Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies
Immune checkpoint inhibitors (ICIs) bring prognostic benefits to patients with malignancies. However, there is a substantial number of patients whose lesions are not improved by ICIs. In addition, ICIs may cause immune‐related adverse events (irAEs), which could lead to an unfavorable prognosis with fatal consequences. Therefore, we conducted a retrospective study to evaluate the utility of circulating sPD‐L1 (soluble programmed cell death 1 ligand 1) as a biomarker in patients with advanced melanoma treated with anti–PD‐1 (programmed cell death 1 protein) antibodies. Sera from 31 consecutive patients were prospectively collected before and after anti–PD‐1 antibody treatment and the serum level of sPD‐L1 was evaluated. We found that high sPD‐L1 levels before treatment were associated with better prognosis, and this association was observed only in patients with a low tumor burden. We also found that sPD‐L1 levels were elevated in patients who developed severe irAEs after treatment, and the patients with severe irAEs had significantly higher fluctuations in sPD‐L1 (delta sPD‐L1) than those without severe irAEs. Our study suggests that serum sPD‐L1 level is a useful biomarker to predict tumor response and irAE development in patients with advanced melanoma treated with anti–PD‐1 antibodies.
- 3 March 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (6) , 807-815
Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies
Immune checkpoint inhibitors (ICIs) bring prognostic benefits to patients with malignancies. However, there is a substantial number of patients whose lesions are not improved by ICIs. In addition, ICIs may cause immune‐related adverse events (irAEs), which could lead to an unfavorable prognosis with fatal consequences. Therefore, we conducted a retrospective study to evaluate the utility of circulating sPD‐L1 (soluble programmed cell death 1 ligand 1) as a biomarker in patients with advanced melanoma treated with anti–PD‐1 (programmed cell death 1 protein) antibodies. Sera from 31 consecutive patients were prospectively collected before and after anti–PD‐1 antibody treatment and the serum level of sPD‐L1 was evaluated. We found that high sPD‐L1 levels before treatment were associated with better prognosis, and this association was observed only in patients with a low tumor burden. We also found that sPD‐L1 levels were elevated in patients who developed severe irAEs after treatment, and the patients with severe irAEs had significantly higher fluctuations in sPD‐L1 (delta sPD‐L1) than those without severe irAEs. Our study suggests that serum sPD‐L1 level is a useful biomarker to predict tumor response and irAE development in patients with advanced melanoma treated with anti–PD‐1 antibodies.
- 7 February 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (4) , 570-573
Pemphigoid without mucous involvement showing IgG antibodies to the β3 subunit of laminin‐332
- 7 February 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (4) , 570-573
Pemphigoid without mucous involvement showing IgG antibodies to the β3 subunit of laminin‐332
- Open Access
- 10 January 2024
- Published by Springer Nature in Cureus
- Vol. 16 (1) , e52052
Pityriasis Rosea With Multiple Herald Patches Resulting in a V-shaped Pattern and a Christmas Tree Distribution
Pityriasis rosea (PR), a benign and self-limiting skin disorder, typically manifests as a single initial lesion known as the herald patch. The herald patch is commonly followed by the development of secondary erythematous papules and plaques, aligning with Langer's lines to form a specific distribution pattern, resembling a Christmas tree on the back and a V-shaped pattern on the upper chest. Therefore, diagnosing PR may not be difficult based on its typical clinical presentation. In contrast, cases of atypical PR presentation have been reported, encompassing several differential diagnoses. Here, we present a case with multiple herald patches that needed differentiation from ringworm, syphilis, and erythema annular centrifugum. Subsequently, our case was diagnosed with PR, as the patches formed a V-shaped pattern and a Christmas-tree distribution.
- 10 January 2024
- Published by Springer Nature in Cureus
- Vol. 16 (1) , e52052
Open AccessPityriasis Rosea With Multiple Herald Patches Resulting in a V-shaped Pattern and a Christmas Tree Distribution
Pityriasis rosea (PR), a benign and self-limiting skin disorder, typically manifests as a single initial lesion known as the herald patch. The herald patch is commonly followed by the development of secondary erythematous papules and plaques, aligning with Langer's lines to form a specific distribution pattern, resembling a Christmas tree on the back and a V-shaped pattern on the upper chest. Therefore, diagnosing PR may not be difficult based on its typical clinical presentation. In contrast, cases of atypical PR presentation have been reported, encompassing several differential diagnoses. Here, we present a case with multiple herald patches that needed differentiation from ringworm, syphilis, and erythema annular centrifugum. Subsequently, our case was diagnosed with PR, as the patches formed a V-shaped pattern and a Christmas-tree distribution.
- Open Access
- 6 December 2023
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 4 (2) , e319
Perforating Collagenosis
We show a case of a 69-year-old man with perforating collagenosis, which is a rare dermatosis commonly associated with diabetes mellitus. Papules and plaques with keratotic plugs are distinctive clinical characteristic of perforating collagenosis. Representative clinical images in our article can enhance the understanding of key concepts of perforating collagenous.
- 6 December 2023
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 4 (2) , e319
Open AccessPerforating Collagenosis
We show a case of a 69-year-old man with perforating collagenosis, which is a rare dermatosis commonly associated with diabetes mellitus. Papules and plaques with keratotic plugs are distinctive clinical characteristic of perforating collagenosis. Representative clinical images in our article can enhance the understanding of key concepts of perforating collagenous.
- 10 November 2023
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 21 (11) , 1405-1406
Radiation‐Recall‐Dermatitis nach Eribulinmesylat
- 10 November 2023
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 21 (11) , 1405-1406
Radiation‐Recall‐Dermatitis nach Eribulinmesylat
- 30 October 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (3) , e61-e62
Metastatic melanoma of the oral cavity showing prompt regression with the use of BRAF/MEK inhibitors
- 30 October 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (3) , e61-e62
Metastatic melanoma of the oral cavity showing prompt regression with the use of BRAF/MEK inhibitors